GlycoMimetics, Inc. (GLYC) stock prices updated...
 

GlycoMimetics, Inc. stock price

GlycoMimetics, Inc. latest news:


  • 12/12/2017 05:42:36

    UPDATE: GlycoMimetics shares soar 30% after positive trial of leukemia treatment

    GlycoMimetics Inc. shares surged 30% in premarket trade Tuesday, after the company reported improvements in median overall survival rates in an early-stage trial of a treatment for acute myeloid leukemia (AML). The company told attendees at the American Society of Hematology annual meeting in Atlanta, Georgia that a trial of 54 patients with relapsed/refractory AML at the Phase 2 dose of its GMI-1271 for whom median follow up was 6.6 months showed clinical remission of 43% and median overall survival of 9.5 months, comparing favorably with historical data. A separate group of 25 older patients with newly diagnosed disease for whom median follow up was 10.5 months had a clinical remission rate of 68%. "These new data from our Phase 1/2 clinical trial demonstrate that encouraging clinical outcomes are possible for both duration of remission and survival endpoints when GMI-1271 is added to chemotherapy in two distinct AML patient populations," noted Helen Thackray, M.D., FAAP, GlycoMimetics clinical development and chief medical officer. "Beyond the high response rates previously reported with GMI-1271, we can now point to additional long-term endpoints that further support our plan to move the drug candidate into a Phase 3 clinical trial scheduled to begin in mid-2018." Shares have gained 135% in 2017, while the S&P 500 has gained 19%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Gogo Inc.GOGO | Golar LNG LimitedGLNG | Golar LNG Partners LPGMLP | Golden Enterprises, Inc.GLDC | Golden Entertainment, Inc.GDEN | Golden Ocean Group LimitedGOGL | Golub Capital BDC, Inc.GBDC | Good Times Restaurants Inc.GTIM | Google Inc.GOOG | Google Inc.GOOGL |